Since no definitive cure for COVID-19 is available so far, one of the challenges against the disease is understanding the clinical features and the laboratory inflammatory markers that can differentiate among different severity grades of the disease. The aim of the present study is a comprehensive and longitudinal evaluation of SCD14-ST and other new inflammatory markers, as well as cytokine storm molecules and current inflammatory parameters, in order to define a panel of biomarkers that could be useful for a better prognostic prediction of COVID-19 mortality. SCD14- ST, as well as the inflammatory markers IL-6, IL-10, SuPAR and sRAGE, were measured in plasma- EDTA of ICU COVID-19 positive patients. In this longitudinal study, SCD14-ST resulted significantly higher in patients who eventually died compared to those who were discharged from the ICU. The results suggest that the new infection biomarker SCD14-ST, in addition to new generation inflammatory biomarkers, such as SuPAR, sRAGE and the cytokines IL-6 and IL-10, can be a useful prognostic tool associated with canonical inflammatory parameters, such as CRP, to predict SARS-CoV-2 outcome in ICU patients.
SCD14-ST and New Generation Inflammatory Biomarkers in the Prediction of COVID-19 Outcome / E. Galliera, L. Massaccesi, L. Yu, J. He, M. Ranucci, M. Corsi Romanelli. - In: BIOMOLECULES. - ISSN 2218-273X. - 12:6(2022 Jun 13), pp. 826.1-826.13. [10.3390/biom12060826]
SCD14-ST and New Generation Inflammatory Biomarkers in the Prediction of COVID-19 Outcome
E. Galliera
Primo
Conceptualization
;L. MassaccesiSecondo
Data Curation
;M. Corsi RomanelliUltimo
Supervision
2022
Abstract
Since no definitive cure for COVID-19 is available so far, one of the challenges against the disease is understanding the clinical features and the laboratory inflammatory markers that can differentiate among different severity grades of the disease. The aim of the present study is a comprehensive and longitudinal evaluation of SCD14-ST and other new inflammatory markers, as well as cytokine storm molecules and current inflammatory parameters, in order to define a panel of biomarkers that could be useful for a better prognostic prediction of COVID-19 mortality. SCD14- ST, as well as the inflammatory markers IL-6, IL-10, SuPAR and sRAGE, were measured in plasma- EDTA of ICU COVID-19 positive patients. In this longitudinal study, SCD14-ST resulted significantly higher in patients who eventually died compared to those who were discharged from the ICU. The results suggest that the new infection biomarker SCD14-ST, in addition to new generation inflammatory biomarkers, such as SuPAR, sRAGE and the cytokines IL-6 and IL-10, can be a useful prognostic tool associated with canonical inflammatory parameters, such as CRP, to predict SARS-CoV-2 outcome in ICU patients.File | Dimensione | Formato | |
---|---|---|---|
biomolecules-12-00826-v3 (3).pdf
accesso aperto
Descrizione: article
Tipologia:
Publisher's version/PDF
Dimensione
1.23 MB
Formato
Adobe PDF
|
1.23 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.